Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.6K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.6K
Master Transcription Regulators02:23

Master Transcription Regulators

7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2.

Cancer science·2026
Same author

Epidermoid Cysts in an Intrapancreatic Accessory Spleen Mimicking Pancreatic Neoplasms: Two Case Reports and a Literature Review of Japanese Cases.

Surgical case reports·2026
Same author

Visionary Leadership in Cancer Care: An Interview With Professor Timothy J. Eberlein.

Annals of gastroenterological surgery·2026
Same author

GDF15 promotes 5-Fluorouracil and Oxaliplatin resistance by promoting stem cell-like phenotype in colorectal cancer.

British journal of cancer·2026
Same author

<i>MiR-155</i>-driven loss of ICOSL and SOCS1 in EBV+ gastric cancers renders abundant cytotoxic T cells ineffective, enabling immune evasion.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair.

Cancer science·2026
Same journal

Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.

Cancer science·2026
Same journal

Splicing Factor Mutations in Clonal Hematopoiesis and Progression to Myeloid Neoplasms.

Cancer science·2026
Same journal

Genetic Evolution in BRCA1-Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis.

Cancer science·2026
Same journal

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response.

Cancer science·2026
Same journal

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4.

Cancer science·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

An Immunofluorescent Method for Characterization of Barrett&#8217;s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.4K

ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation.

Tadashi Abe1,2, Takaaki Masuda1,3, Taro Tobo4

  • 1Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.

Cancer Science
|October 22, 2025
PubMed
Summary
This summary is machine-generated.

Zinc finger protein 282 (ZNF282) drives colorectal cancer (CRC) progression by promoting cell cycle and is linked to poor prognosis. Targeting ZNF282 may offer new therapeutic strategies for CRC patients.

Keywords:
E2F1cell cyclecell proliferationcolorectal cancerzinc finger protein 282 (ZNF282)

More Related Videos

Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

3.2K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.9K

Related Experiment Videos

Last Updated: Jan 14, 2026

An Immunofluorescent Method for Characterization of Barrett&#8217;s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.4K
Zebrafish Model of Neuroblastoma Metastasis
05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

3.2K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) remains a significant global health challenge, necessitating novel therapeutic targets.
  • Understanding the genetic drivers of CRC progression is crucial for developing effective treatments.

Purpose of the Study:

  • To identify and characterize novel genes involved in colorectal cancer (CRC) progression.
  • To investigate the role of zinc finger protein 282 (ZNF282) in CRC development and its potential as a prognostic biomarker and therapeutic target.

Main Methods:

  • Comprehensive gene expression profiling using The Cancer Genome Atlas (TCGA) and single-cell RNA sequencing.
  • CRISPR/Cas9-mediated ZNF282 knockout in CRC cell lines for in vitro and in vivo experiments.
  • Spatial transcriptomics and motif scanning to elucidate ZNF282's mechanism of action.

Main Results:

  • ZNF282 is overexpressed in CRC tumors and associated with distant metastasis and poor prognosis.
  • ZNF282 knockout significantly reduces CRC tumor growth and cell proliferation by impairing cell cycle progression (G1/S transition).
  • ZNF282 downregulates E2F1 and its downstream targets (CCNE1, CCND1), suggesting a regulatory role in cell cycle control.

Conclusions:

  • ZNF282 is a novel oncogene promoting CRC progression, potentially through E2F1 activation and cell cycle enhancement.
  • High ZNF282 expression serves as an independent poor prognostic factor in CRC.
  • ZNF282 represents a promising prognostic biomarker and therapeutic target for colorectal cancer.